Algernon Pharmaceuticals (AGNPF)
OTHER OTC:AGNPF

Algernon Pharmaceuticals (AGNPF) Stock Price & Analysis

72 Followers

AGNPF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.04 - $0.17
Previous Close$0.09
Volume2.10K
Average Volume (3M)14.21K
Market Cap
$1.98M
Enterprise Value$1.92M
Total Cash (Recent Filing)C$76.28K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)
Beta0.71
Jul 26, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding20,015,762
10 Day Avg. Volume13,163
30 Day Avg. Volume14,215
Standard Deviation0.29
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

47.32%0.00%0.00%52.68%
47.32% Insiders
0.00% Other Institutional Investors
52.68% Public Companies and
Individual Investors

AGNPF FAQ

What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was $0.04 and its highest was $0.17 in the past 12 months.
    What is Algernon Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Algernon Pharmaceuticals’s upcoming earnings report date?
    Algernon Pharmaceuticals’s upcoming earnings report date is Jul 26, 2024 which is today.
      How were Algernon Pharmaceuticals’s earnings last quarter?
      Algernon Pharmaceuticals released its earnings results on Apr 29, 2024. The company reported -$0.037 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.037.
        Is Algernon Pharmaceuticals overvalued?
        According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Algernon Pharmaceuticals pay dividends?
          Algernon Pharmaceuticals does not currently pay dividends.
          What is Algernon Pharmaceuticals’s EPS estimate?
          Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Algernon Pharmaceuticals have?
          Algernon Pharmaceuticals has 21,840,721 shares outstanding.
            What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
            Algernon Pharmaceuticals reported an EPS of -$0.037 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
              Currently, no hedge funds are holding shares in AGNPF
              ---

              Algernon Pharmaceuticals Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Algernon Pharmaceuticals

              Algernon Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the development of repurposed therapeutic drugs. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, and idiopathic pulmonary fibrosis. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Axsome Therapeutics
              Insmed
              SELLAS Life Sciences Group
              Molecular Templates
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis